Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xuanfei Baidu Granules
- Development stage
- Unknown
- Lead developer
- Buchang Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xuanfei Baidu Granules (XFBD) is a proprietary Traditional Chinese Medicine (TCM) formulation developed for the treatment of respiratory infections and inflammatory lung conditions. Originally formulated during the COVID-19 pandemic as one of the "Three Formulas and Three Medicines" (San Yao San Fang), it was approved by the National Medical Products Administration (NMPA) of China in March 2021 for the treatment of mild to moderate COVID-19. The preparation is a complex mixture of herbal extracts, including *Ephedra sinica*, *Armeniaca sibirica*, *Gypsum fibrosum*, and *Coix lacryma-jobi*, among others. Its mechanism of action involves multi-target modulation of inflammatory pathways, reduction of cytokine storms, and improvement of lung function. Beyond COVID-19, XFBD is being evaluated in Phase III clinical trials for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) as an adjunct to standard Western therapies.
- Brand names
- Xuanfei Baidu Granules
- Other names
- Xuanfei Baidu FormulaXuanfei Baidu DecoctionXuanfei Baidu
02
Targets
IL-17A (Interleukin-17A)GM-CSF (Granulocyte-macrophage colony-stimulating factor)Mpro (3C-like proteinase of SARS-CoV-2)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)GPR18 (G protein-coupled receptor 18)
Beyond the preview
Go deeper on Xuanfei Baidu Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xuanfei Baidu Granules.